Autopsy report · NCT05423106

A Single and Multiple Ascending Dose Study of JNJ-64457744

“Strategic business decision, not due to safety concerns”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 9 months before it stopped.
• 60 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Janssen Research & Development, LLC

Sponsor type

Industry

Conditions

Healthy; Hepatitis B, Chronic

Interventions

JNJ-64457744; Placebo; Tenofovir Disoproxil Fumarate (TDF); Tenofovir Alafenamide (TAF); Entecavir (ETV); JNJ-64457744

Participants

60

Sites

1

Countries

New Zealand

Trials that died the same way

• The KHENERGYC Study
  “Strategic company decision - not related to safety concerns” (93% match in meaning)
• Investigational Study of Delayed Release Metformin
  “Strategic company decision - not related to a safety concern” (93% match in meaning)
• Efficacy and Time and Resources for Hylenex-facilitated SC Rehydration Versus ORT for Dehydrated Children in the Emergency Department (ED)
  “Strategic business decision (not related to safety or efficacy concerns)” (91% match in meaning)
• Treatment of Impulsive Aggression (IA) in Adolescent With ADHD in Conjunction With Standard ADHD Treatment
  “Business decision, not related to safety” (88% match in meaning)
• A Study of RBI-4000 in Healthy Participants
  “Strategic business decision (not related to safety, efficacy, or quality)” (87% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.